PharmiWeb.com - Global Pharma News & Resources

Pharmaco - Press Releases

Date Title Company
31-Aug-2022 Nordic Nanovector ASA Results for the Second Quarter and First Half 2022 Nordic Nanovector
31-Aug-2022 Kinarus Therapeutics Reports H1 2022 Financial Results and Provides Corporate Update Kinarus Therapeutics
31-Aug-2022 New Engagement Grants to Inspire the Next Generation of Scientists Cambridge Crystallographic Data Centre (CCDC)
31-Aug-2022 Immutep granted Japanese patent for Eftilagimod Alpha, a soluble LAG-3 protein, in combination with a PD-1 pathway inhibitor Immutep
31-Aug-2022 Original-Research: M1 Kliniken AG (von First Berlin Equity Research GmbH) M1 Kliniken AG
31-Aug-2022 Laverock Therapeutics founded to develop the next generation of programmable cell therapies Sciad Newswire
31-Aug-2022 Spexis announces presentation of half-year 2022 financial results and participation at upcoming industry and investor events in September Spexis AG
31-Aug-2022 Kinarus Therapeutics Reports H1 2022 Financial Results and Provides Corporate Update Kinarus Therapeutics Holding AG
30-Aug-2022 Vita 34 records moderate upward trend in the second quarter Vita 34 AG
30-Aug-2022 Heidelberg Pharma AG Raises Approximately EUR 80 Million From Capital Measure Heidelberg Pharma AG
30-Aug-2022 Original-Research: Formycon AG (von First Berlin Equity Research GmbH) Formycon AG
30-Aug-2022 OKYO Pharma Plans Q4 2022 IND Filing of OK-101 to treat Dry Eye Disease with Subsequent Phase 2 Initiation Alongside Peptide Manufacturing Partner, AmbioPharm OKYO Pharma
30-Aug-2022 FDA grants priority review to efanesoctocog alfa for people with hemophilia A Sanofi
30-Aug-2022 European Commission Approves FYB201/Ranivisio®1 (Ranivisio - Ranibizumab), a Biosimilar to Lucentis®2 Polpharma Biologics
29-Aug-2022 Vita 34 lowers sales and earnings guidance due to IFRS 15 effect and accelerated restructuring measures Vita 34 AG
29-Aug-2022 CHEPLAPHARM INCREASES REVENUE AND EARNINGS IN THE FIRST HALF OF 2022eplapharm AG: Cheplapharm AG
29-Aug-2022 Uni-Bio Science Group Limited: 2022 Interim Results UNI-BIO SCIENCE GROUP LIMITED
29-Aug-2022 Moderna, Inc.: Swissmedic Authorizes Moderna’s Omicron-Targeting Bivalent Booster Candidate, MRNA-1273.214 Moderna, Inc.
29-Aug-2022 European Commission approves FYB201/Ranivisio®1 (Ranivisio - Ranibizumab), a biosimilar to Lucentis®2 (news with additional features) Formycon AG
29-Aug-2022 European Commission Approves FYB201/Ranivisio®(1) (Ranivisio - Ranibizumab), a Biosimilar to Lucentis®(2) B3C newswire